CAR-T cell therapy for advanced gynecological cancers
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a new type of immunotherapy called CAR-T cells for advanced ovarian, uterine, or other gynecological cancers that have not responded to standard treatments. The CAR-T cells are specially designed to target proteins (MUC1, MSLN, PD-L1) found on cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a gynecological cancer (like ovarian or uterine) that has spread and has not responded to standard treatments, or you cannot tolerate those treatments.
- A recent tissue sample from your tumor shows high levels of MUC1, MSLN, or PD-L1 proteins.
- You are a woman between 18 and 70 years old.
- Your overall health is fairly good, with a performance status of 0 or 1 (meaning you can care for yourself and walk around).
- Your blood counts, liver, kidney, heart, and lung function are within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a lab-made immune therapy (CAR-T) that targets a protein called CD70 found on some advanced cancers. It’s designed for people whose solid tumors have spread and no standard treatments have worked or weren’t tolerated.
This trial tests a new type of 'fast CAR-T' cell therapy for people with advanced solid tumors that have not been helped by standard treatments. CAR-T cells are a kind of immune cell that is reprogrammed to attack cancer cells that carry certain markers called mesothelin, MUC1, and PD-L1.
This trial tests a new treatment called CAR-T cells that target a protein called CD70 found on some gynecologic cancer cells. It is for people whose cancer has advanced or spread and has not responded to or stopped responding to standard treatments.
This Phase 1 study tests CAR-T cells that are engineered to recognize several cancer “markers” (specific proteins) found on some advanced cancers. It may help by directing the patient’s own immune cells to attack cancer, but eligibility depends on matching the required protein markers.
This trial tests a new type of immune cell therapy (CAR-T cells) designed to target two markers on cancer cells at once. The goal is to help patients with advanced solid tumors where standard treatments have stopped working or aren't an option.
This early-phase trial tests CAR-T cells designed to attack tumors that have high HER2 and PD-L1. It may help people with certain solid cancers that have not responded well to standard treatment.
Hear when a new Gynecological Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.